Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Abstract: The present invention provides a method for treating a disease or condition in a mammal which comprises the steps of; administering a therapeutically effective amount of a T type calcium channel inhibitor to effectively slow or stop progression of eukaryotic cells through the S, G2 and M phases of the cell cycle to increase the proportion of the eukaryotic cells in the G1 phase, stopping administration of the T type calcium channel inhibitor for a period of time, and administering a dosage selected from the group consisting of a dosage of at least one chemotherapeutic agent, a dosage of radiation, and combinations thereof, to kill the proportion of eukaryotic cells progressing past the G1 phase of the cell cycle after the stopping of the administration of the T type calcium channel inhibitor.

Abstract: The use of dihydropyridine-5-phosphonic acid cyclic propylene ester derivatives of formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug in the treatment of cancers, pre-cancerous conditions and other conditions is disclosed, wherein each of R1-R8 are the same or different, are hydrogen or C1-C6 alkyl; one of X1 and X2 is nitro while the other is hydrogen; each of Y1 and Y2 may be the same or different, is phenyl which may be substituted by chlorine, fluorine or alkoxy; and m and n are integers from 0-4, a prodrug thereof, or a pharmaceutically acceptable salt thereof.